We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Targeted therapeutics drug discovery and development company Arrien Pharmaceuticals has entered a worldwide license agreement with an unnamed US-based pharmaceutical firm for the clinical agent ARN-6039.